



## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/529,871	FIRST NAMED APPLICANT Mathias Bergman	ATTY. DOCKET NO. 014975-114
---	--	--------------------------------


21839  
BUCHANAN INGERSOLL PC  
(INCLUDING BURNS, DOANE, SWECKER & MATHIAS)  
POST OFFICE BOX 1404  
ALEXANDRIA, VA 22313-1404

014975-114

RLG/SMD/BTP

Sequence Listing Due 9/21/05

Date Mailed: 07/21/2005



INTERNATIONAL APPLICATION NO. PCT/FI03/00723
---

LA. FILING DATE 10/03/2003	PRIORITY DATE 10/03/2002
-------------------------------	-----------------------------

CONFIRMATION NO. 2270

371 FORMALITIES LETTER



\*OC000000016566608\*

**URGENT**

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required

application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*


SHAKEEL AHMED

Telephone: (703) 308-9140 EXT 208

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/529,871	PCT/FI03/00723	014975-114

FORM PCT/DO/EO/922 (371 Formalities Notice)



**Patent Response Postcard**

78


Inventor: Mathias Bergman et al. Appln. No.: 10/529,871 Filing Date: April 1, 2005  
Docket No.: 014975-114 Working Atty.: Susan M. Dadio/jamyn Date: September 21, 2005  
Dkt. Clerk Initials

The following was/were received in the U.S. Patent and Trademark Office on the date stamped hereon:

- |  |   |   |
|--|---|---|
| <input checked="" type="checkbox"/> Transmittal Letter for Response to Notice to Comply with Sequence Listing Requirements | <input checked="" type="checkbox"/> Copy of Notice dated July 21, 2005. | <input type="checkbox"/> Check for \$ _____ is enclosed                             |
| <input type="checkbox"/> and Preliminary Amendment (in dup.)   | <input type="checkbox"/>  | <input type="checkbox"/> Check for \$ _____ is enclosed                             |
| <input checked="" type="checkbox"/> Response to Notice to Comply with SL Requirements and Preliminary Amendment            | <input type="checkbox"/>  | <input type="checkbox"/> Charge \$ _____ to Deposit Account                         |
| <input checked="" type="checkbox"/> Substitute Paper Copy of Sequence Listing attached to Preliminary Amendment            | <input type="checkbox"/>  | <input type="checkbox"/> Charge \$ _____ to credit card. Form PTO-2038 is attached. |
| <input checked="" type="checkbox"/> Declaration Pursuant to 37 C.F.R. Sections 1.821-1.825                                 | <input type="checkbox"/>  | <input type="checkbox"/> Filed by Certificate of Mail                               |
| <input checked="" type="checkbox"/> Diskette containing computer readable copy of Sequence Listing.                        | <input type="checkbox"/>  | <input type="checkbox"/>  |
|  |   | <input type="checkbox"/>  |
|  |   | <input type="checkbox"/>  |

If submitting documents via Express Mail, provide the Express Mailing Label No. below:  
**Express Mail Mailing Label No.**





Patent  
Attorney's Docket No. 014975-114

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	<b>MAIL STOP: SEQUENCE</b>
	)	
Mathias BERGMAN et al.	)	Group Art Unit: Unassigned
	)	
Application No.: 10/529,871	)	Examiner: Unassigned
	)	
Filed: April 1, 2005	)	Confirmation No.: 2270
	)	
For: TUMOR TARGETING AGENTS	)	
AND USES THEREOF	)	

**TRANSMITTAL LETTER FOR RESPONSE TO NOTICE TO COMPLY  
WITH SEQUENCE LISTING REQUIREMENTS AND PRELIMINARY AMENDMENT**

**MAIL STOP: SEQUENCE**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In complete response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed on July 21, 2005, enclosed please find:

- [X] A Response to Notice to Comply with Sequence Listing Requirements and Preliminary Amendment (with attached paper copy of substitute Sequence Listing).
- [X] A Declaration Pursuant to 37 C.F.R. §§ 1.821-1.825.
- [X] A diskette containing a computer readable version of the Sequence Listing.
- [X] A copy of the Notice mailed on July 21, 2005.


The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL PC  
Including attorneys from Burns, Doane, Swecker & Mathis

Date: September 21, 2005

By: \_\_\_\_\_

  
Susan M. Dadio  
Registration No. 40,373

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620



IFW  
Box  
SEC

Patent

Attorney's Docket No. 1014975-000114

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
Mathias Bergman et al.	)	Group Art Unit: Unassigned
Application No.: 10/529,871	)	Examiner: Unassigned
Filing Date: April 1, 2005	)	Confirmation No.: 2270
Title: TUMOR TARGETING AGENTS	)	
AND USES THEREOF	)	

**REQUEST FOR WITHDRAWAL OF HOLDING OF  
ABANDONMENT - NO ABANDONMENT IN FACT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with M.P.E.P. § 711.03, withdrawal of the holding of abandonment in the above-captioned application is respectfully requested, there being no abandonment in fact. Specifically, the Notice of Abandonment mailed on February 28, 2007 states that the application is held abandoned for failure to respond to the U.S. Patent and Trademark Office communication mailed on July 21, 2005. The July 21, 2005 communication was a notice to comply with the sequence listing requirements.

However, a reply to the July 21, 2005 communication was timely filed on September 21, 2005. A copy of that reply (*i.e.*, Transmittal Letter for Response to Notice to Comply with Sequence Listing Requirements and Preliminary Amendment, Response to Notice to Comply with Sequence Listing Requirements and Preliminary Amendment, Declaration Pursuant to 37 C.F.R. Sections 1.821-1.825, diskette mailer which originally contained a computer readable version of the Sequence Listing, and the Notice dated July 21, 2005) is enclosed, as is a copy of a postcard

receipt date-stamped by the U.S. Patent and Trademark Office acknowledging receipt of said reply on said date. This date-stamped postcard receipt, which itemizes and properly identifies the papers filed, is *prima facie* evidence of receipt in the U.S. Patent and Trademark Office of all the items listed thereon on the date stamped thereon by the U.S. Patent and Trademark Office. See M.P.E.P. § 503. For the convenience of the U.S. Patent and Trademark Office, we have enclosed herewith another copy of the diskette containing the computer readable version of the sequence listing.

In light of the above, withdrawal of the holding of abandonment and prompt and favorable action on the merits are respectfully requested.

It is believed that no fee is required for consideration of this paper. Should the Office deem otherwise, the Director is hereby authorized to charge any appropriate fees under 37 C.F.R. § 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: May 29, 2007

By:

  
Susan M. Dadi

Registration No. 40373

P.O. Box 1404  
Alexandria, VA 22313-1404  
703 836 6620